This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Trius Therapeutics To Present Data From Drug Development Programs At ICAAC

SAN DIEGO, Sept. 7 /PRNewswire/ -- Trius Therapeutics, Inc. (Nasdaq: TSRX) announced today that the results of multiple studies from its drug development programs, including its lead antibiotic drug candidate torezolid phosphate (TR-701), will be presented in poster presentations at the 50th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) meeting in Boston September 12-15. In addition to the results of clinical and nonclinical studies of torezolid phosphate, the posters highlight advances in Trius' preclinical GyrB and DHFR antibacterial and antifungal programs.

The presentations are as follows:

Sunday, September 12th

Poster Presentations 002 – Pharmacology of Oxazolidinones and Miscellaneous Antibacterial Agents ( 11:30 a.m.1:30 p.m.)

  • A1-013: Absolute Bioavailability of TR-701 FA and Pharmacokinetics after Single and Multiple Intravenous Administration in Healthy Adult Subjects; P. Bien, P. Prokocimer, K.A. Munoz, C. Bethune
  • A1-014: Population Pharmacokinetic Modeling of TR-700 in Patients with Complicated Skin and Skin Structure Infections; J. Mondick, P. Bien, C. De Anda, M. Gastonguay, P. Prokocimer

Monday, September 13th

Poster Presentation 080 – Antibiotic Therapy of Serious Bacterial Infections in Animal Models ( 11:15 a.m.1:15 p.m.)

  • B-709: Anti-Virulence Effect of TR-700 on MRSA Strains Causing Complicated Skin and Skin Structure Infections (cSSTIs); J. M. Yamaki, T. Synold, A. Wong-Beringer

Poster Presentations 092 – Inhibitors of Metabolic Processes ( 11:15 a.m.1:15 p.m.)

  • F1-834: Structure-based Design of Novel 7-substituted Diaminoquinazoline Antibacterial Agents Targeting Dihydrofolate Reductase (DHFR); M. Hilgers, T. Lam, J. Zhang, X. Li, Z. Chen, M. Trzoss, C. Creighton, L. Kohen, M. Cunningham, B. Kwan, K. Nelson, M. Stidham, V. Brown-Driver, K. Shaw, J. Finn
  • F1-835: Structure-Based Design of New DHFR Antibacterial Agents (Part 1):  7-Aryl-2,4-Diaminoquinazolines SAR; X. Li, M. Hilgers, J. Zhang, Z. Chen, T. Lam, M. Trzoss, L. Kohen, C. Creighton, M. Cunningham, K. Nelson, B. Kwan, M. Stidham, V. Brown-Driver; K. Shaw, J. Finn
  • F1-836: Structure-Based Design of New DHFR Antibacterial Agents (Part 2):  7-Benzimidazol-1-yl-2,4-Diaminoquinazolines SAR; J. Finn, T. Lam, J. Zhang, M. Hilgers, X. Li, M. Trzoss, L. Kohen, M. Cunningham, K. Nelson, M. Stidham, V. Brown-Driver, K. Shaw
  • F1-837: Microbiological Profile of Novel 2,4-diaminoquinazoline DHFR Inhibitors; V. Brown-Driver, T. Lam, K. Nelson, A. Castellano, C. Creighton, J. Zhang, X. Li, Z. Chen, M. Trzoss, K. GC, E. Biller, M. Cunningham, M. Stidham, K. Shaw,  J. Finn
  • F1-838: Advanced Microbiology and In Vivo Efficacy of Rx101005, a Novel 2,4-Diaminoquinazoline DHFR Inhibitor; V. Brown-Driver, T. Lam, A. Castellano, K. Nelson, K. Shaw, J. Finn

Poster Presentations 093 – New Antifungal Agents ( 11:15 a.m.1:15 p.m.)

  • F1-855: Evaluation of Novel 2,4-Diaminoquinazoline Inhibitors of Candida albicans DHFR; M. Cunningham, M. Hilgers, B. Kwan, K. Nelson, T. Lam, J. Zhang, X. Li, Z. Chen, M. Trzoss, C. Creighton, L. Kohen K. Shaw, J. Finn

Tuesday, September 14th

Poster Presentations 169 – Antibiotic Resistance in Gram-Negative Bacteria Other than Enterobacteriacea ( 11:15 a.m.1:15 p.m.)

  • C1-1426: Evidence for Multiple Functionality of Campylobacter jejuni DNA Gyrase in Chromosomal Replication; D. Bensen, A. Walters, M. Cunningham, L. Tari, K. Shaw, J. Finn

Poster Presentations 170 – Antibiotic Resistance in Staphylococcus aureus ( 11:15 a.m.1:15 p.m.)

  • C1-1431: Elevated Linezolid Resistance in Clinical Staphylococcus aureus cfr Isolates is Associated with Co-Occurring Mutations in Ribosomal Protein L3; J. Locke, G. Morales, M. Hilgers, K. GC, M. Rahawi, J. J. Picazo, K. J. Shaw, J. Stein
  • C1-1432: Structure-Activity Relationships of Diverse Oxazolidinones for Linezolid-Resistant Staphylococcus aureus Strains Possessing Ribosomal Mutations or the cfr Methyltransferase Gene; J. Locke, J. Finn, M. Hilgers, K. GC, M. Rahawi, G. Morales, J. J. Picazo, W. IM, K. Shaw, and J. Stein

Copies of these posters will be available on the Trius website following the ICAAC meeting:

About Trius Therapeutics

Trius Therapeutics is a biopharmaceutical company focused on the discovery, development and commercialization of innovative antibiotics for serious, life-threatening infections. The company's lead product candidate, torezolid phosphate, is an IV and orally administered second generation oxazolidinone in Phase 3 clinical development for the treatment of acute bacterial skin and skin structure infections (ABSSSI), the first such trial to be initiated under a Special Protocol Assessment (SPA). In addition to the company's torezolid phosphate clinical program, it is currently conducting two preclinical programs using its proprietary discovery platform to develop antibiotics to treat infections caused by gram-negative bacteria. For more information, visit

SOURCE Trius Therapeutics, Inc.

Copyright 2009 PR Newswire. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 18,053.71 +23.50 0.13%
S&P 500 2,088.77 +6.89 0.33%
NASDAQ 4,806.8590 +33.3870 0.70%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs